Medipharm Labs Corp Stock Performance
| MEDIF Stock | USD 0.05 0 3.85% |
Medipharm Labs has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -1.07, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Medipharm Labs are expected to decrease slowly. On the other hand, during market turmoil, Medipharm Labs is expected to outperform it slightly. Medipharm Labs Corp right now secures a risk of 4.1%. Please verify Medipharm Labs Corp maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Medipharm Labs Corp will be following its current price movements.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Medipharm Labs Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable forward indicators, Medipharm Labs is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 19.9 M | |
| Total Cashflows From Investing Activities | 35 K | |
| Free Cash Flow | -14 M |
Medipharm |
Medipharm Labs Relative Risk vs. Return Landscape
If you would invest 4.96 in Medipharm Labs Corp on August 26, 2024 and sell it today you would earn a total of 0.04 from holding Medipharm Labs Corp or generate 0.81% return on investment over 90 days. Medipharm Labs Corp is currently producing 0.0952% returns and takes up 4.1013% volatility of returns over 90 trading days. Put another way, 36% of traded otc stocks are less volatile than Medipharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Medipharm Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medipharm Labs' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Medipharm Labs Corp, and traders can use it to determine the average amount a Medipharm Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0232
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | MEDIF | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.1 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Medipharm Labs is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medipharm Labs by adding it to a well-diversified portfolio.
Medipharm Labs Fundamentals Growth
Medipharm OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Medipharm Labs, and Medipharm Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medipharm OTC Stock performance.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (2.07) % | |||
| Operating Margin | (1.61) % | |||
| Current Valuation | 3.05 M | |||
| Shares Outstanding | 280.51 M | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 21.71 M | |||
| EBITDA | (38.55 M) | |||
| Cash And Equivalents | 21.99 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 1.44 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.22 X | |||
| Cash Flow From Operations | (13.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Total Asset | 92.36 M | |||
About Medipharm Labs Performance
By analyzing Medipharm Labs' fundamental ratios, stakeholders can gain valuable insights into Medipharm Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medipharm Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medipharm Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada. MEDIPHARM LABS is traded on OTC Exchange in the United States.Things to note about Medipharm Labs Corp performance evaluation
Checking the ongoing alerts about Medipharm Labs for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Medipharm Labs Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medipharm Labs Corp has some characteristics of a very speculative penny stock | |
| Medipharm Labs Corp had very high historical volatility over the last 90 days | |
| The company reported the revenue of 21.71 M. Net Loss for the year was (54.8 M) with loss before overhead, payroll, taxes, and interest of (13.42 M). | |
| Medipharm Labs Corp has accumulated about 21.99 M in cash with (13.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Medipharm Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medipharm Labs' stock is overvalued or undervalued compared to its peers.
- Examining Medipharm Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medipharm Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medipharm Labs' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Medipharm Labs' otc stock. These opinions can provide insight into Medipharm Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medipharm OTC Stock analysis
When running Medipharm Labs' price analysis, check to measure Medipharm Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medipharm Labs is operating at the current time. Most of Medipharm Labs' value examination focuses on studying past and present price action to predict the probability of Medipharm Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medipharm Labs' price. Additionally, you may evaluate how the addition of Medipharm Labs to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |